Drugs / HEXAVAC™
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Withdrawn | EU (EMA) | Hexavac | — | 2012-06-28 | europa.eu ↗ |
| Approved | EU (EMA) | Hexavac | — | 2000-10-23 | europa.eu ↗ |
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT01457547 Comparator | Oct 2003 → May 2005 | diphtheria, haemophilus infectious disease, hepatitis B virus infection, poliomyelitis +1 | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HEXAVAC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01457547 ↗ |
| Known as | DTPa-HBV-IPV-Hib vaccine | “DTPa-HBV-IPV-Hib vaccine (HEXAVAC™)” NCT01457547 ↗ |
| Modality | Vaccine | “INFANRIX™ HEXA and HEXAVAC™ vaccines” NCT01457547 ↗ |